Enanta Pharmaceuticals, Inc. reported its financial results for the fiscal third quarter ended June 30, 2025. The company announced a net loss of $18.3 million for the quarter.
Despite the reported net loss, Enanta Pharmaceuticals topped revenue estimates for the fiscal third quarter. This indicates a continued trend of managing operational costs while exceeding revenue expectations.
Additionally, the company announced the completion of enrollment in the RSVHR trial, a proof-of-concept study of zelicapavir in high-risk adults infected with RSV. This milestone signifies progress in the clinical development of a key pipeline asset.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.